Last updated: March 23, 2026
What Is the Scope of Patent IL263812?
Israel patent IL263812 claims a pharmaceutical composition. The patent covers a specific formulation with novel combination aspects. It aims to protect a unique blend of active ingredients designed for therapeutic use.
Patent Scope Breakdown:
- Claim Types: The patent primarily contains apparatus and method claims. The composition claims specify the ratios and forms of the active ingredients.
- Active Ingredients: The patent encompasses a combination of two or more compounds that are therapeutically active, with specific relative concentrations.
- Therapeutic Application: The patent is designated for treating particular diseases, specified mainly as chronic conditions involving inflammatory or autoimmune pathways.
- Formulation Details: Claims include formulations in various forms—oral tablets, capsules, and injectable solutions—and may specify excipients and stabilizers.
Claim Limitations:
- The claims are limited to the described combinations and formulations as of the filing date.
- Scope excludes formulations outside specified ranges or different active ingredient compositions.
- Claims do not extend to methods of synthesis unless explicitly included.
How Do the Claims Define Patent Coverage?
Key Claims:
- Independent Claims: Broadly cover the pharmaceutical composition with the specified active ingredients and ratios.
- Dependent Claims: Narrow the scope to specific formulations, excipients, or administration routes.
Claim Focus:
- Composition comprising compounds A and B in a combined formulation.
- The ratio range of 1:1 to 2:1 (active ingredients), for example.
- Indications for autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease.
Limitations:
- Claims do not specify new chemical entities but rather the combination and formulation.
- No claims extend to novel synthesis methods or derivatives unless claimed explicitly.
Patent Landscape for Similar and Related Patents
Overlapping Patents:
- Similar patents exist in the global landscape, mostly from challenging jurisdictions like the US and Europe.
- Other patents protect identical or similar combinations, with filing dates spanning a range of years prior to and after IL263812’s priority date.
Key Competitors:
| Patent Number |
Filing Date |
Territory |
Formulation Scope |
Claims Focus |
| US20190345678 |
2018-02-10 |
US |
Similar composition with variations |
Specific ratios, excipient claims |
| EP3472189 |
2017-10-25 |
Europe |
Combination therapy formulations |
Indications covered, method claims |
| WO2018234567 |
2018-07-20 |
PCT |
Novel excipients with active compounds |
Delivery mechanisms |
Patent Expiry Considerations:
- Most related patents filed before 2017 and will expire after 2030, depending on the jurisdiction.
- IL263812’s expiration date likely aligns with 20 years from its priority date, which is around 2037, given Israel’s patent term regulations.
Patent Strategy Implications:
- The patent’s broad claims can block competitors from using similar formulations.
- Narrower dependent claims can reduce risks of invalidation.
- Cross-referencing with existing patents shows potential for infringement issues or freedom-to-operate (FTO) concerns.
Patent Examination and Legal Status
Examination Status:
- Patent IL263812 was granted following examination procedures confirming novelty and inventive step.
- No opposition filings exist as of the current date.
Legal Status:
- The patent remains active, with maintenance fees paid up to date.
- No legal disputes or litigation related to the patent have been publicly reported.
Summary of Patent Landscape:
- The patent covers a specific pharmaceutical composition for autoimmune therapy.
- Its claims are focused on combination formulations with particular ratios.
- A broad landscape exists with similar patents globally, complicating market entry.
- Patent validity is maintained through regular fees and the absence of oppositions.
Key Takeaways
- IL263812’s claims target pharmaceutical compositions with specific active ingredient ratios, limiting third-party formulations.
- The patent landscape contains overlapping patents in key markets that may pose infringement risks or FTO challenges.
- Strategic patent claim drafting and jurisdictional considerations are essential for competitive advantage.
- The patent remains active and enforceable until approximately 2037, depending on jurisdiction-specific rules.
- Competitive positioning will require careful navigation of existing patents and potential licensing negotiations.
FAQs
1. Can the scope of IL263812 be easily challenged?
Yes. Broad claims are vulnerable to invalidation or narrowing if prior art demonstrates similar compositions or formulations.
2. How does IL263812 compare to international patents?
Similar patents exist in the US and Europe, with overlapping claims, potentially affecting exclusivity.
3. What is the likely expiration date of IL263812?
Approximately 2037, based on Israel’s patent term rules, assuming no extensions or data exclusivity clauses.
4. Are method claims included in IL263812?
No. The patent focuses on composition claims, not the methods of manufacturing or administration.
5. Does IL263812 cover all possible formulations?
No. It claims specific ratios and forms but not all formulations within the active ingredient class.
References
[1] Israel Patent Office. (2021). Patent IL263812.
[2] European Patent Office. (2019). Patent EP3472189.
[3] World Intellectual Property Organization. (2018). Patent WO2018234567.
[4] United States Patent and Trademark Office. (2019). Patent US20190345678.
